Introduction
Angiogenesis, or the formation of new blood vessels, is a characteristic trait of many cancers, involving a wide variety of pathways [1, 2] . Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) have been the target of Electronic supplementary material The online version of this article (doi:10.1007/s00259-017-3793-2) contains supplementary material, which is available to authorized users. many clinical attempts to curtail angiogenesis, with varying levels of success in nearly every type of cancer [3] [4] [5] . These treatments, often utilizing bevacizumab, induce responses in a subpopulation of patients; however, even these responders often progress [6, 7] .
CD105, or endoglin, is an endothelial cell marker that has been suggested to be a suitable biomarker for angiogenesis, as well as a possible therapeutic target [8] [9] [10] . As CD105 has a very limited biodistribution in normal tissue [11] , it has become an attractive target for both treatment and imaging of angiogenic tumors [12] . TRC105, a human/murine chimeric antibody targeting CD105, has been clinically studied in a wide variety of cancers in phase I and II trials [13] [14] [15] [16] [17] . While limited toxicity has been observed in patients enrolled in these studies, clinical activity of TRC105 alone has also been rather limited, with minimal benefit being reported from this drug as monotherapy. The use of TRC105 in anticancer therapy in combination with other anticancer treatments is thus being explored.
One such option for enhancing the efficacy of TRC105 is the addition of a beta-emitting radionuclide such as 177 Lu (t 1/2 6.65 days, E max 0.497 MeV) for targeted radionuclide therapy. Unlike external beam radiation treatments, in which the exact location of a tumor needs to be known, radioimmunotherapy depends on knowledge of the biology of a cancer, regardless of its location within the body [18, 19] . This means that such targeted strategies are feasible for metastatic disease, or for tumors in radiation-sensitive areas. Ideal targets for radioimmunotherapy are preferentially expressed on cancerous tissue with minimal normal tissue expression, as in the case of CD105. Potential therapeutic targets on cancer cells are easily identified through biopsy, which is nearly always performed for primary tumors. Antiangiogenic agents have been combined with both external and targeted radiotherapy with success as a dual treatment preclinically [20] [21] [22] , and VEGF targeting has also been studied for potential radioimmunotherapy [23, 24] . CD105-targeted agents hold promise for the treatment of a number of cancers, as CD105 expression has been noted in many tumor types [11] . We therefore present here a widely applicable targeted radionuclide therapy agent based upon TRC105 for targeting angiogenesis in therapy with 177 Lu.
Methods and materials

Antibody chelation and determination of radiolabeling conditions
T h e a n t i -C D 1 0 5 a n t i b o d y, T R C 1 0 5 ( T R A C O N Pharmaceuticals) was obtained commercially. The antibody was prepared for radiolabeling by conjugation with the monofunctional versions of either DOTA or DTPA (Macrocyclics) using standard methods [12] . 177 LuCl 3 was obtained from Perkin Elmer. As both DOTA and DTPA may be employed for chelation of 177 Lu (t 1/2 6.65 days), radiolabeling efficiencies were compared. Various ratios of antibody to isotope (from 0.05 μg/μCi to 0.5 μg/μCi) were incubated for various times from 5 to 60 min, and labeled and unlabeled fractions were quantified using instant thin-layer chromatography (iTLC). Similar procedures were used for radiolabeling the nonspecific isotype-matched antibody, 177 Lu-DTPA-IgG (Invitrogen).
Flow cytometry
Flow cytometry was used to evaluate the binding of TRC105 and DTPA-TRC105 to 4T1 cells (CD105-negative) and human umbilical vein endothelial cells (HUVECs, CD105-positive). Cells were prepared and stained according to previously reported procedures [25] . The following control groups were included: cells alone, cells incubated with secondary antibody alone (goat anti-human AlexaFluor488; Invitrogen), and cells incubated with a nonspecific IgG isotype control antibody (Invitrogen). Samples were tested using a BD FACSAria cell sorter, and data were analyzed using FlowJo V10 software.
Murine breast cancer models 4T1 murine breast cancer cells were purchased from the American Type Culture Collection and maintained in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine serum. Cells were incubated at 37°C in an atmosphere containing 5% CO 2 , and used for in vivo experiments when they reached nearly 75% confluence.
All animal studies were conducted with the approval of the University of Wisconsin -Madison Institutional Animal Care and Use Committee. To generate the breast cancer model, female Balb/c mice (Harlan) at 4-5 weeks of age were implanted with 2 × 10 6 4T1 cells in a 1:1 mixture of Matrigel (BD Biosciences) in the lower flank. Mice were monitored and used for therapeutic studies 10 days after implantation when the tumors had reached 5-10 mm in diameter.
Therapy preparation and administration
DTPA-TRC105 and DTPA-IgG were radiolabeled with 177 Lu using procedures similar to those described previously [26] . In summary, 177 LuCl 3 was diluted in sodium acetate buffer (pH 6.5) and 0.15 μg/μCi DTPA-TRC105 (or DTPA-IgG) was added. The reactants were incubated for 1 h at 37°C with constant shaking and purified via a PD-10 column (GE Healthcare) prior to preparation for injection.
Five study groups were used for the in vivo therapy study, as outlined in Table 1 . Mice received a single injection of the therapeutic agent in a total volume of 100 μL in PBS via a tail vein.
Monitoring of treatment safety and efficacy
Every other day, the body weight, tumor volume (measured with calipers), and general appearance of the mice in all study groups were evaluated. Mice were killed by CO 2 asphyxiation if the tumor volume increased to >500% of its initial size, body weight decreased by more than 15%, or hindlimb movement was significantly impaired by the tumor. Complete blood count analyses and liver function tests were performed in untreated mice as well as those in the high-dose treatment group a month after therapy administration.
Biodistribution studies were performed to determine the organs of localization of 177 Lu-DTPA-TRC105 at both 1 day and 7 days after injection. Mice were killed after the appropriate number of days, and various organs were excised, wetweighed, and gamma counting was performed using a WIZARD2 automatic gamma counter (PerkinElmer). Uptake is presented as percent injected dose per gram (%ID/ g). Biodistribution studies were also performed on radionuclide-injected mice in all groups as they were killed throughout the study.
Ex vivo tissue sample analysis
Tumor, liver, and kidney tissue samples were collected from mice in the high-dose 177 Lu-DTPA-TRC105 group at various times for histological evaluation as described previously [25] . Tissues were embedded and frozen in Optimal Cutting Temperature compound (Sakura Fintek) and sectioned in 7-μm slices. Immunofluorescent staining was performed on tumor tissues to look for the presence of angiogenesis and existing blood vessel structure, using AlexaFluor488-conjugated anti-CD31 and DyLight550-conjugated anti-CD105 antibodies (Novus Biologicals). H&E staining was also performed on the same tissues to look for morphological evidence of damage from the treatment.
Dosimetric extrapolation
The biodistributions of 89 Zr-labeled and 64 Cu-labeled TRC105 have previously been reported by our group [12, 27] . Using the longitudinal PET tracer uptake from these studies in conjunction with biodistribution data for 177 Lu-DTPA-TRC105, a conservative estimate of dose to a tumor following injection of 177 Lu-DTPA-TRC105 was calculated using the dose-to-sphere modeling capabilities of OLINDA/ EXM [28] .
Statistical analysis
Direct comparisons between groups were performed using a two-sided Student's t test. Data are presented as means ± standard deviation. A P value less than 0.05 was considered statistically significant.
Results
Radiolabeling conditions and choice of chelator for 177 
Lu
The efficiencies of radiolabeling of TRC105 conjugated with DOTA or with DTPA were compared. As shown in Fig. 1a , higher labeling yields were achieved with DTPA than with DOTA for all antibody-to-isotope ratios and all reaction time points. After 1 h incubation, labeling yields of >90% were achieved with the use of all DTPA-TRC105 antibody ratios over 0.1 μg/μCi as determined by iTLC, while DOTA-TRC105 yields were only near 90% for 0.5 μg/μCi (DTPA, Fig. 1b ; DOTA not shown). Thus, a ratio of 0.15 μg of DTPA-TRC105 for every 1 μCi of 177 Lu was used. For therapy and biodistribution studies, similar labeling yields were consistently achieved. Flow cytometry studies indicated no sacrifice in binding of TRC105 to HUVECs with the addition of the DTPA chelator (Fig. 1c, d ). Flow cytometry studies also showed that TRC105 specifically bound only to endothelial cells, and not to 4T1 cancer cells themselves. A small amount of binding to HUVECs was noted for the nonspecific IgG.
Biodistribution studies
Gamma counting biodistribution studies were performed at 1 and 7 days after injection of 177 Lu-DTPA-TRC105 in 4T1 tumor-bearing mice. As shown in Fig. 2 , the radioactivity uptake by various organs was determined. Persistent uptake Lu-DTPA-TRC105 in tumor tissue (14.3 ± 2.3%ID/g and 11.6 ± 6.1%ID/g, respectively; n = 3). The agent cleared from the blood pool over the course of the week, with uptake values of 18.5 ± 3.1%ID/g on day 1 after injection and 10.5 ± 3.9%ID/g on day 7. Similar decreases in uptake were seen in other clearance organs such as the liver and kidneys over the course of the week. In mice injected with the nonspecific antibody, 1 77 Lu-DTPA-IgG, tumor uptake of 9.9 ± 4.1%ID/g was observed on day 7 after injection. Sizable accumulations were also observed in the spleen (14.7 ± 3.4%ID/g) and bone (10.7 ± 3.9%ID/g), which may have contributed to the notable toxicity in this group. In the other control groups, biodistribution studies were performed as the mice were killed (average 13-14 days after injection; Fig. 2b ).
177
LuCl 3 was found to localize mainly in the liver and spleen, with very minimal uptake in tumor (0.1 ± 0.03%ID/g). Biodistribution of low-dose 177 Lu-DTPA-TRC105 was found to match that of high-dose The treatment efficacy of 177 Lu-DTPA-TRC105 was determined using 4T1 murine breast cancer models. Mice received a single injection of the given agent via a tail vein, and tumor volume was monitored every other day. As outlined in Table 1 Lu-DTPA-TRC105 than in mice in groups 1 and 2 at 10 days after injection (or 20 days after tumor inoculation), when the first mouse in these groups was killed having met the criteria described above. Tumor volumes were also smaller in mice in low-dose group 3 than in mice in 177 Lu-only group 1 at this time point (p = 0.02). This inhibition of tumor growth in mice in the high-dose group led to a corresponding increase in survival, which was significantly longer than in mice in any other group (p < 0.001; Fig. 3 ). Mice in group 5 had an average survival of 32.4 ± 4.8 days, while mice in groups 1, 2, 3, and 4 had shorter survivals of 13 ± 2.2, 13.3 ± 1.9, 14 ± 1.8, and 8 ± 3.7 days, respectively. Most mice in groups 1, 2, 3, and 5 were killed on the basis of tumor growth, as none displayed significant weight loss; however, one mouse each in groups 2 and 5 was killed due to significant hindlimb impairment prior to Lu-DTPA-IgG in 4T1 tumor-bearing mice. Gradual clearance is seen in most organs, with tumor uptake of the targeted tracer remaining high over the 7-day period at approximately 11-14%ID/g (n = 3). Notable differences in uptake for the nonspecific IgG are seen in the spleen and bone at 7 d after injection, as compared to the targeted tracer. b As mice were killed, biodistribution studies were performed in the other control groups. These data were collected at an average of 13 days after injection in the 177 Lu only group, and 14 days after injection in the low-dose group (n = 4-6 per group) Fig. 3 Results of the therapeutic study. a Average (± standard deviation) tumor volumes in mice in all study groups over the first 12 days of the study. Mice in the high-dose group showed significantly (p < 0.05) smaller tumor volumes than mice in all other groups at 12 days after injection.
b Body weights of all mice were measured every other day. c KaplanMeier survival curves for mice in each therapeutic group. d Mice in the high-dose group showed significantly longer average survival than those in all other groups (p < 0.001) the tumor volume increasing by 500%. On the other hand, the majority of mice in group 4 ( 177 Lu-DTPA-IgG) were killed due to significant weight loss and corresponding toxicity of the nonspecific tracer.
Toxicity and safety determination
The safety of 177 Lu-DTPA-TRC105 was monitored in various experiments over the course of the study. Body weights were monitored to check for systemic toxicity every other day, and the weight of any individual mouse did not decrease by more than 10% over the course of the study in groups 1, 2, 3, or 5. Most mice in these groups were near their original pretherapy weight at the time they were killed. However, in group 4, mice injected with the nonspecific antibody demonstrated noticeable toxicity due to off-target accumulation and three (of five) mice were killed when their body weight decreased by >15%.
Complete blood counts and alanine transaminase (ALT) levels were determined before and 1 month after treatment in the high-dose 177 Lu-DTPA-TRC105 group (Fig. S1 ). Notably, a sizable increase was noted in monocyte levels, resulting from inflammation during the course of treatment. ALT levels remained nearly constant, indicating no liver toxicity.
Immunohistochemistry
Tumor tissues were collected at 1, 7, and 30 days after injection from mice in the high-dose 177 Lu-DTPA-TRC105 group.
Fluorescent immunochemical staining of these tissues was performed to evaluate CD105 and CD31 expression (Fig. 4) . No CD105 staining was observed in tissues collected on both day 1 and day 7 after injection, suggesting destruction of this receptor through targeting with 177 Lu-DTPA-TRC105. At 1 month after injection, when tumors had recommenced growth, angiogenesis was evident at the periphery of the tumors, visualized through CD105 costaining with blood vessels in this region. Morphological differences were also noted over the course of the study on H&E staining (Fig. S3) .
Dosimetry
Utilizing biodistribution data from previous studies [12, 27] of radiolabeled TRC105 in conjunction with the biodistribution from the study described here, approximate doses to tumors following administration of 177 Lu-DTPA-TRC105 were calculated ( Supplementary Fig. 2 ). As biodistributions of TRC105 labeled with the positron emitter and with the beta emitter were similar, all available data were combined to obtain a larger dataset for more accurate dosimetry estimation. For example, in this study, tumors at the start of therapy in group 5 had an average volume of 0. 
Discussion
Targeted radiotherapy has a number of advantages over other cancer treatment options, including its specificity for diseased tissue and very localized dose deposition [18] . Such strategies are gaining traction in the clinic, notably through peptide receptor targeting in difficult neuroendocrine tumors [29] . Most radioimmunotherapy treatments utilize targets that are very specific for a given cancer, rather than a general approach that may be more widely applicable. CD105, or endoglin, is one such general target which has been identified in a wide variety of cancers, and may be correlated with overall outcomes [8] [9] [10] [11] . The CD105-targeting monoclonal antibody employed in this study, TRC105, has been explored as a single therapeutic agent, with limited success. It was therefore hypothesized that the addition of a dose-depositing nuclide would increase the therapeutic efficacy.
The use of murine mammary cancer models allowed the exploration of the therapeutic efficacy of 177 Lu-DTPA-TRC105. Of course, as with any model system, it should be noted that this tracer will need to be thoroughly investigated in another tumor model or organism. It was found that a single injection of a sufficient dose of this agent significantly slowed tumor growth, as compared to tumor growth in mice in the control groups. Mice in the high-dose group survived for an average of 32.4 ± 4.8 days, in contrast to 14 ± 1.8 days in mice in the low-dose group (that received three times less 177 Lu). Mice in the control groups of 177 Lu alone, TRC105 alone, and a radiolabeled nonspecific IgG antibody similarly had shorter survivals (13 ± 2.2, 13.3 ± 1.9, and 8 ± 3.7 days, respectively). Taken together, the increase in survival in mice in the highdose group indicates the efficacy of this treatment.
In all groups except the nonspecific IgG group, no evidence of significant toxicity was observed. The body weights of the mice did not significantly decrease, and the blood counts indicated minimal differences in toxicity markers. In the nonspecific group, the agent notably accumulated in both the spleen and the bone marrow, both of which may have contributed to the significant toxicity (indicated by extreme weight loss) observed in this group. Off-target accumulation of radioimmunotherapy agents is a considerable concern; however, the limited normal tissue distribution of CD105 minimizes this risk with this agent. Even though a single dose of 177 Lu-DTPA-TRC105 was unable to completely eradicate solid tumors in this study, significant tumor growth inhibition was observed. This agent may thus find application in combination with other agents for its ability to slow tumor growth to allow other agents to be more effective. Possible additional therapies to combine with radioimmunotherapy may include checkpoint immunotherapy [30] and chemotherapeutic approaches [31] [32] [33] , which have shown benefit both preclinically and in human studies. Of note, the absorbed doses estimated for this tracer are lower than those for other 177 Lu-labeled antibodies [34, 35] ; however, the efficacy that was observed may have been due in part to the combined effects of radiotherapy and the biological effect of TRC105 itself, a phenomenon which is further supported by the lack of tumor inhibition in the nonspecific IgG group.
The low expression of CD105 in normal tissues also allows high-contrast imaging of CD105 through the use of molecular imaging techniques, as we have previously demonstrated [12, 27, 36, 37] . Thus, this single antibody may serve as a theranostic agent, with diagnostic capabilities resulting from conjugation with positron-emitting isotopes such as Lulabeled TRC105 was found to be similar to that of previously reported PET imaging with TRC105, indicating that this image-then-treat approach is feasible. This personalized approach would be widely applicable in multiple solid tumor types, allowing targeted therapy and real-time monitoring of response. Clinical translation of this versatile approach may also be expedited, as TRC105 itself is already in clinical trials.
Conclusion
We have developed a radioimmunotherapy agent, 177 Lu-DTPA-TRC105, targeting angiogenic tissues through CD105. Significantly extended survival was observed in the treatment group, with corresponding slowed tumor growth and negligible toxicity. We believe that such an agent will show widely applicable clinical utility in combination with other treatments, in many solid cancer types. In addition, the theranostic capabilities of TRC105 merit further investigation through clinical trials.
Compliance with ethical standards
Financial support This work was supported, in part, by the University of Wisconsin -Madison, the National Institutes of Health (NIBIB/NCI 1R01CA169365, 1R01EB021336, P30CA014520, 5T32GM08349, T32GM008505), the National Science Foundation (DGE-1256259) and the American Cancer Society (125246-RSG-13-099-01-CCE).
Conflicts of interest C.P. Theuer is the CEO of TRACON Pharmaceuticals. No potential conflicts of interest were disclosed by the other authors.
Ethical approval All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
